OncoMatch/Clinical Trials/NCT04884035
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Is NCT04884035 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for lymphoma, b-cell.
Treatment: CC-220 · Rituximab · Cyclophosphamide · Doxorubicin · Vincristine · Prednisone · CC-99282 · Polatuzumab vedotin · Rituximab — This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21. A polatuzumab-R-CHP regimen in combination with CC-220 or CC-99282 will be explored with the addition of a new cohort only after the RP2D for the CC-220 and/or CC-99282 and R-CHOP-21 combination has been defined.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L or ≥ 1.0 x 10^9/L with >50% bone marrow involvement, without growth factor support for 7 days (14 days if peg-G-CSF); Hemoglobin ≥ 8 g/dL; Platelets ≥ 75 x 10^9/L or ≥ 50 x 10^9/L with >50% bone marrow involvement, without transfusion for 7 days.
Kidney function
Estimated serum creatinine clearance (CrCl) of ≥ 50 mL/min using MDRD formula.
Liver function
AST/SGOT and ALT/SGPT ≤ 2.5 x ULN; ≤ 5.0 x ULN if documented liver involvement by lymphoma. Serum total bilirubin ≤ 2.0 mg/dL except in cases of Gilbert's syndrome, then ≤ 5.0 mg/dl. For polatuzumab vedotin: serum total bilirubin < 1.5 × ULN (26 μmol/L), except in cases of Gilbert's syndrome, then ≤ 3.0 mg/dl (51 μmol/L).
Cardiac function
Left ventricular ejection fraction (LVEF) < 45% as determined by MUGA or ECHO is exclusionary.
Participants must have the following laboratory values: ... (see above for details). Impaired cardiac function or clinically significant cardiac disease, including any of the following: LVEF < 45% as determined by MUGA or ECHO.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic - Arizona · Scottsdale, Arizona
- Local Institution - 169 · Duarte, California
- Mayo Clinic - Jacksonville · Jacksonville, Florida
- Mayo Clinic Jacksonville - PPDS · Jacksonville, Florida
- University Of Kansas Medical Center · Kansas City, Kansas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify